The Significance of Liquid Biopsy in Pancreatic Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2018 Oct 2

PMID 30271504

Citations 25

Authors

Zi-Hao Qi

Hua-Xiang Xu

Shi-Rong Zhang

Jin-Zhi Xu

Shuo Li

He-Li Gao

Wei Jin

Wen-Quan Wang

Chun-Tao Wu

Quan-Xing Ni

Xian-Jun Yu

Liang Liu

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of cancer. The 5-year survival rate for PDAC remains low because it is always diagnosed at an advanced stage and it is resistant to therapy. A biomarker, which could detect asymptomatic premalignant or early malignant tumors and predict the response to treatment, will benefit patients with PDAC. However, traditional biopsy has its limitations. There is an urgent need for a tumor biomarker that could easily and repeatedly sample and monitor, in real time, the progress of tumor development. Liquid biopsy could be a tool to assess potential biomarkers. In this review, we focused on the latest discoveries and advancements of liquid biopsy technology in pancreatic cancer research and demonstrated how this technology is being used in clinical applications.

Citing Articles

High sensitivity tapered fiber refractive index biosensor using hollow gold nanoparticles.

Borjikhani P, Granpayeh N, Zibaii M Sci Rep. 2025; 15(1):1458.

PMID: 39789159 PMC: 11717910. DOI: 10.1038/s41598-025-85739-z.

Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma-A New Tool for Molecular Profiling of Mutations in Tumor and Plasma Samples.

Bravo A, Morao B, Luz A, Dourado R, Oliveira B, Guedes A Cancers (Basel). 2024; 16(20).

PMID: 39456638 PMC: 11506488. DOI: 10.3390/cancers16203544.

Clinical Application of Liquid Biopsy in Pancreatic Cancer: A Narrative Review.

Ramirez-Maldonado E, Lopez Gordo S, Major Branco R, Pavel M, Estalella L, Llacer-Millan E Int J Mol Sci. 2024; 25(3).

PMID: 38338919 PMC: 10855073. DOI: 10.3390/ijms25031640.

A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma.

Stosic K, Azurmendi Senar O, Tarfouss J, Bouchart C, Navez J, Van Laethem J Cells. 2024; 13(1).

PMID: 38201207 PMC: 10778087. DOI: 10.3390/cells13010003.

Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer-Advances and Challenges.

Seyhan A Int J Mol Sci. 2023; 24(17).

PMID: 37686149 PMC: 10488102. DOI: 10.3390/ijms241713340.

References

San Lucas F, Allenson K, Bernard V, Castillo J, Kim D, Ellis K . Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol. 2015; 27(4):635-41. PMC: 4803451. DOI: 10.1093/annonc/mdv604. View

Allenson K, Castillo J, San Lucas F, Scelo G, Kim D, Bernard V . High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017; 28(4):741-747. PMC: 5834026. DOI: 10.1093/annonc/mdx004. View

Ren C, Han C, Zhang J, He P, Wang D, Wang B . Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. Cancer Biol Ther. 2011; 12(8):700-6. DOI: 10.4161/cbt.12.8.15960. View

Catenacci D, Chapman C, Xu P, Koons A, Konda V, Siddiqui U . Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015; 149(7):1794-1803.e4. PMC: 4985007. DOI: 10.1053/j.gastro.2015.08.050. View

Gerlinger M, Rowan A, Horswell S, Math M, Larkin J, Endesfelder D . Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366(10):883-892. PMC: 4878653. DOI: 10.1056/NEJMoa1113205. View

Goonetilleke K, Siriwardena A . Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2006; 33(3):266-70. DOI: 10.1016/j.ejso.2006.10.004. View

Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M . Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2017; 25(2):155-161. DOI: 10.1002/jhbp.524. View

Ntouroupi T, Ashraf S, McGregor S, Turney B, Seppo A, Kim Y . Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008; 99(5):789-95. PMC: 2528135. DOI: 10.1038/sj.bjc.6604545. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

10.

Schwarzenbach H, Hoon D, Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11(6):426-37. DOI: 10.1038/nrc3066. View

11.

Greystoke A, Ayub M, Rothwell D, Morris D, Burt D, Hodgkinson C . Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Mol Oncol. 2015; 10(2):282-91. PMC: 4750526. DOI: 10.1016/j.molonc.2015.10.004. View

12.

Kulemann B, Pitman M, Liss A, Valsangkar N, Fernandez-Del Castillo C, Lillemoe K . Circulating tumor cells found in patients with localized and advanced pancreatic cancer. Pancreas. 2015; 44(4):547-50. DOI: 10.1097/MPA.0000000000000324. View

13.

Bissolati M, Sandri M, Burtulo G, Zorzino L, Balzano G, Braga M . Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumour Biol. 2014; 36(2):991-6. DOI: 10.1007/s13277-014-2716-0. View

14.

Sikora K, Bedin C, Vicentini C, Malpeli G, DAngelo E, Sperandio N . Evaluation of cell-free DNA as a biomarker for pancreatic malignancies. Int J Biol Markers. 2014; 30(1):e136-41. DOI: 10.5301/jbm.5000088. View

15.

Pietrasz D, Pecuchet N, Garlan F, Didelot A, Dubreuil O, Doat S . Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res. 2016; 23(1):116-123. DOI: 10.1158/1078-0432.CCR-16-0806. View

16.

Poruk K, Valero 3rd V, Saunders T, Blackford A, Griffin J, Poling J . Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg. 2016; 264(6):1073-1081. PMC: 4936958. DOI: 10.1097/SLA.0000000000001600. View

17.

Long J, Luo G, Xiao Z, Liu Z, Guo M, Liu L . Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett. 2014; 346(2):273-7. DOI: 10.1016/j.canlet.2014.01.004. View

18.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

19.

Ting D, Wittner B, Ligorio M, Vincent Jordan N, Shah A, Miyamoto D . Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014; 8(6):1905-1918. PMC: 4230325. DOI: 10.1016/j.celrep.2014.08.029. View

20.

Gattani A, Mandeli J, Bruckner H . Tumor markers in patients with pancreatic carcinoma. Cancer. 1996; 78(1):57-62. DOI: 10.1002/(SICI)1097-0142(19960701)78:1<57::AID-CNCR10>3.0.CO;2-6. View